Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol

American Journal of Hematology

Volumn 48, Issue 4, 1995, Pages 213-220

  Glueck, Charles J ^a   Freiberg, Richard ^a   Glueck, Helen I ^a   Tracy, Trent ^a   Stroop, Davis ^a   Wang, Ying ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

hypofibrinolysis; lipoprotein (a) Lp(a) ; osteonecrosis; osteonecrosis (ON); plasminogen activator inhibitor; plasminogen activator inhibitor (PAI); Stanozolol; tissue plasminogen activator (tPA)

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; STANOZOLOL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BONE NECROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HIP; HUMAN; HYPOFIBRINOLYSIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; CASE REPORT; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HIP; HUMAN; LIPOPROTEIN(A); MALE; MIDDLE AGE; OSTEONECROSIS; PLASMINOGEN INACTIVATORS; STANOZOLOL; SUPPORT, NON-U.S. GOV'T;

EID: 0028914541     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.2830480402     Document Type: Article

References (38)

1. Nontraumatic necrosis of bone (osteonecrosis)
2. Intravascular coagulation and osteonecrosis
3. A microangiographic study of idiopathic osteonecrosis of the femoral head
4. Osteonecrosis
5. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip
6. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
7. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor
8. Hypofibrinolysis: A common, major cause of osteonecrosis
9. Osteonecrosis of the femoral head. Pathogenesis and long‐term results of treatment
10. Bone marrow oedema syndrome and transient osteoporosis of the hip: An MRI‐controlled study of treatment by core decompression
11. Osteonecrosis of the femoral head: A prospective randomized treatment protocol
12. Making core decompression work
13. A diagnostic algorithm for osteonecrosis of the femoral head
14. Multimodality approach to osteonecrosis of the femoral head
15. Nontraumatic avascular necrosis of the femoral head: Past, present, and future
16. Association of alcohol intake, cigarette smoking, and occupational status with the risk of idiopathic osteonecrosis of the femoral head
17. MRI appearance of femoral head osteonecrosis following core decompression and bone grafting
18. Capacitive coupling as an adjunctive treatment for avascular necrosis
19. Osteonecrosis of the femoral head: Results of core decompression and grafting with and without electrical stimulation
20. Early diagnosis of avascular necrosis of the femoral head
21. Management of avascular necrosis of the femoral head: An overview
22. Fibrinolytic enhancement with stanozolol fails to improve symptoms and signs in patients with post‐surgical back pain
23. Idiopathic osteonecrosis, hypofibrinolysis, high lipoprotein(a), and therapy with Stanozolol
24. Treatment of hereditary protein C deficiency with stanozolol
25. Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency
26. The effects of oral stanozolol on fibrinolysis in type 2 diabetes mellitus
27. Stanozolol‐induced changes in fibrinolysis and coagulation in healthy adults
28. The Centers for Disease Control–National Heart, Lung and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements
29. Enzymatic determination of total serum cholesterol
30. A peroxidasecoupled method for the colorimetric determination of serum triglycerides
31. 2
32. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultra centrifuge
33. Measurement of serum Apo A1 and Apo B: Comparison of immunoturbidimetric and rate nephelometric techniques
34. Relationship between Lp(a), lipids, apolipoproteins, and fibrinolytic activity in 191 hyperlipidemic patients
35. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia
36. The fibrometer system of routine coagulation tests
37. Transient osteoporosis of the hip: Clinical and imaging features